769 related articles for article (PubMed ID: 16968347)
21. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics.
Ooteman W; Koeter MW; Verheul R; Schippers GM; van den Brink W
Eur Neuropsychopharmacol; 2007 Jul; 17(8):558-66. PubMed ID: 17379484
[TBL] [Abstract][Full Text] [Related]
22. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
Soyka M; Chick J
Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
Bouza C; Angeles M; Muñoz A; Amate JM
Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
[TBL] [Abstract][Full Text] [Related]
24. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
25. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
Mason BJ; Goodman AM; Chabac S; Lehert P
J Psychiatr Res; 2006 Aug; 40(5):383-93. PubMed ID: 16546214
[TBL] [Abstract][Full Text] [Related]
26. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
27. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators.
Ooteman W; Naassila M; Koeter MW; Verheul R; Schippers GM; Houchi H; Daoust M; van den Brink W
Addict Biol; 2009 Jul; 14(3):328-37. PubMed ID: 19523047
[TBL] [Abstract][Full Text] [Related]
28. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
[TBL] [Abstract][Full Text] [Related]
29. Medications for treating alcohol dependence.
Williams SH
Am Fam Physician; 2005 Nov; 72(9):1775-80. PubMed ID: 16300039
[TBL] [Abstract][Full Text] [Related]
30. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
[TBL] [Abstract][Full Text] [Related]
32. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
33. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
34. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Soyka M; Preuss U; Schuetz C
Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
[TBL] [Abstract][Full Text] [Related]
35. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
Schmidt LG; Smolka MN
Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
37. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.
Martinotti G; Di Nicola M; Di Giannantonio M; Janiri L
J Psychopharmacol; 2009 Mar; 23(2):123-9. PubMed ID: 18515460
[TBL] [Abstract][Full Text] [Related]
38. Naltrexone in the treatment of alcohol dependence.
Krystal JH; Cramer JA; Krol WF; Kirk GF; Rosenheck RA;
N Engl J Med; 2001 Dec; 345(24):1734-9. PubMed ID: 11742047
[TBL] [Abstract][Full Text] [Related]
39. [The pharmacologic treatment of the alcohol dependence].
Castro LA; Baltieri DA
Braz J Psychiatry; 2004 May; 26 Suppl 1():S43-6. PubMed ID: 15729444
[TBL] [Abstract][Full Text] [Related]
40. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?
Kiefer F; Jahn H; Otte C; Naber D; Wiedemann K
Biol Psychiatry; 2006 Jul; 60(1):74-6. PubMed ID: 16483549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
